8-K: Bausch Health to Acquire DURECT Corporation in $63 Million Upfront Cash Deal with Up to $350 Million in Contingent Value Rights

Bausch Health Americas, Inc. will acquire DURECT Corporation for $1.75 per share in cash plus one non-tradeable contingent value right per share, potentially adding up to $350 million in milestone payments related to larsucosterol net sales.

Summary

• DURECT Corporation entered into an Agreement and Plan of Merger with Bausch Health Americas, Inc. and BHC Lyon Merger Sub, Inc. on July 28, 2025.
• Merger Sub will commence a tender offer by August 11, 2025, to acquire all DURECT common shares for $1.75 per share in cash, plus one non-tradeable Contingent Value Right (CVR) per share.
• Each CVR represents the contractual right to receive a pro rata portion of two potential additional net sales milestone payments totaling up to $350 million in the aggregate.
• Net Sales Milestone #1: $100 million payable upon aggregate worldwide annual net sales of larsucosterol reaching at least $500 million in any one calendar year.
• Net Sales Milestone #2: $250 million payable upon aggregate worldwide annual net sales of larsucosterol reaching at least $1 billion in any one calendar year.
• Milestones must be achieved before the earlier of the 10-year anniversary of the first commercial sale in the United States and December 31, 2045.
• The DURECT Board unanimously determined the transaction is in the best interests of the Company and its stockholders and recommends tendering shares.
• The offer is not subject to a financing condition.
• Following the tender offer, Merger Sub will merge into DURECT, with DURECT surviving as a wholly-owned subsidiary of Parent, without a stockholder vote.
• Outstanding DURECT stock options will be canceled and converted into cash (for in-the-money options) and a right to a portion of a retention bonus pool based on milestone achievement.
• A retention plan for certain key service providers, including senior management, was approved on July 28, 2025, linking cash retention bonuses to the achievement of the larsucosterol net sales milestones.
• The upfront cash consideration for the acquisition is approximately $63 million.
• The purchase price represents a premium of approximately 191% to the 30-day volume-weighted average trading price of DURECT's common stock ending July 28, 2025, and approximately 217% to the trading price on July 28, 2025.

Sentiment

Score: 8

Explanation: Highly positive due to the substantial premium offered to shareholders and the significant upside potential from the CVRs, despite the non-tradable nature of the CVRs and the inherent risks of drug development. The strategic fit for Bausch Health and the addressing of an unmet medical need also contribute to positive sentiment.

Positives

• The acquisition offers a substantial premium to DURECT shareholders: approximately 191% to the 30-day volume-weighted average trading price and 217% to the trading price on July 28, 2025.
• Shareholders have the potential to receive significant additional payments of up to $350 million through Contingent Value Rights (CVRs) tied to larsucosterol net sales milestones.
• Larsucosterol has received FDA Breakthrough Therapy Designation, highlighting its potential importance and accelerated development pathway for alcoholic hepatitis.
• The acquisition strategically strengthens Bausch Health's commitment and existing expertise in hepatology, complementing its ongoing Phase 3 program for rifaximin SSD.
• The transaction is not subject to a financing condition, ensuring the availability of funds for the acquisition.
• A retention plan has been approved for key DURECT employees, including senior management, aligning their incentives with the successful achievement of larsucosterol milestones.

Negatives

• The Contingent Value Rights (CVRs) are non-tradeable, limiting liquidity and immediate value realization for shareholders.
• Parent (Bausch Health) retains sole discretion and decision-making authority over whether to continue to invest in, develop, market, or sell larsucosterol, which could impact the achievement of CVR milestones.
• There is no assurance that any CVR milestones will be achieved, or that payment will be required, as they are contingent on future net sales performance.
• The CVR agreement has a defined term, terminating upon the earlier of the 10-year anniversary of the first commercial sale in the United States or December 31, 2045, limiting the timeframe for milestone achievement.

Risks

• Uncertainties regarding the timing and completion of the tender offer and the merger.
• Uncertainties regarding the percentage of DURECT stockholders tendering their Company Shares in the Offer.
• The possibility that competing offers for DURECT will be made.
• The possibility that various closing conditions for the Offer or the Merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable regulatory and/or governmental entities (or any conditions, limitations, or restrictions placed on such approvals).
• Risks relating to DURECT's liquidity during the pendency of the Offer and the Merger or in the event of a termination of the Merger Agreement.
• The risk that the Milestone Payments for the CVRs are not achieved.
• The effects of disruption caused by the transaction making it more difficult to maintain relationships with employees, collaborators, partners, vendors, and other business partners.
• Risks related to diverting management's attention from DURECT's ongoing business operations.
• The risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense.

Future Outlook

A registrational Phase 3 program for larsucosterol in severe alcoholic hepatitis is being planned, with a randomized, double-blind, placebo-controlled, multi-center study design and a primary endpoint of 90-day survival. Efficacy and safety results for Bausch Health's rifaximin SSD Phase 3 program, assessing its efficacy to delay onset of first overt hepatic encephalopathy hospitalization and all-cause mortality in cirrhotic patients, are expected in early 2026.

Management Comments

• "This announcement is fundamental progress on our Strategic Priority—Innovation, which is to intensify focus and operating rigor behind R&D and business development and demonstrates our commitment to hepatology and finding new ways to address unmet medical needs, living our purpose of enriching lives through our relentless drive to deliver better health outcomes for patients." Thomas J. Appio, Chief Executive Officer, Bausch Health.
• "There is a significant unmet need in the treatment of patients with AH given the high mortality rate and that there are no currently approved treatments. We are very excited to add larsucosterol, an asset which has FDA Breakthrough Therapy Designation, to our pipeline, particularly as it builds on our existing expertise within the hepatology space. It is complementary to our ongoing Phase 3 program of soluble solid dispersion of rifaximin (rifaximin SSD) being studied in cirrhotic patients globally." Jonathan Sadeh M.D., M.Sc., Executive Vice President, Chief Medical Officer and Head of R&D, Bausch Health.
• "AH, by our estimates, is responsible for about 100 deaths per day in the US and billions of dollars in healthcare costs. Since we reported results from our Phase 2b AHFIRM clinical trial for larsucosterol in AH, our primary focus has been advancing larsucosterol towards the completion of clinical development. We chose this transaction with Bausch Health because we believe it provides significant value for our stakeholders, both immediately and in the long term, should larsucosterol be approved and achieve commercial success. We view Bausch Health as the right partner to advance larsucosterol due to their expertise in hepatology, commercial success with Xifaxan and experienced development team. We look forward to the potential impact larsucosterol could have for patients with AH and the medical community that cares for them. Thank you to our team at DURECT and our partners that have helped advance larsucosterol to this point." James E. Brown, D.V.M., President and CEO, DURECT.
• "The addition of larsucosterol to our pipeline is a strategic fit with our focus in hepatology and underscores our continued dedication to exploring and identifying new treatments for individuals who are suffering with liver disease and its complications. We are excited to continue investment in bringing these breakthrough options to market, not just in the US, but also globally." Aimee Lenar, Executive Vice President of US Pharma, Bausch Health.

Industry Context

The acquisition of DURECT and its lead asset, larsucosterol, addresses a significant unmet medical need in the treatment of alcoholic hepatitis (AH), a life-threatening liver disease with no currently FDA or EMA approved treatments. This move strengthens Bausch Health's position in hepatology, complementing its existing Phase 3 program for rifaximin SSD, which targets hepatic encephalopathy in cirrhotic patients. The transaction highlights a strategic focus on developing innovative solutions for liver disease complications, a growing area of concern in healthcare.

Comparison to Industry Standards

• The acquisition offers a substantial premium of approximately 191% to DURECT's 30-day volume-weighted average trading price and 217% to its prior day closing price, which is significantly higher than typical acquisition premiums in the biopharmaceutical sector, reflecting the perceived value of larsucosterol.
• Larsucosterol's FDA Breakthrough Therapy Designation positions it as a potentially first-in-class therapeutic for alcoholic hepatitis, an area currently lacking approved treatments, unlike many other therapeutic areas with established competitors.
• Bausch Health's existing commercial success with Xifaxan in gastroenterology and its ongoing Phase 3 rifaximin SSD program for hepatic encephalopathy provide a strong, established infrastructure and expertise in hepatology, which is a key differentiator compared to smaller companies or those without a dedicated liver disease focus.
• The contingent value rights (CVRs) structure, while common in biotech acquisitions, is notable for its non-tradable nature, which differs from some CVRs that allow for secondary market trading, potentially limiting immediate liquidity for DURECT shareholders.

Management Changes

Corporate Governance

Legal Proceedings

• The filing mentions the risk of stockholder litigation in connection with the transactions contemplated by the Merger Agreement, which may result in significant costs of defense.
• The Company will promptly advise Parent of any such proceedings and give Parent the opportunity to consult or participate in the defense or settlement, with the Company requiring Parent's consent for settlement.

Related Party Transactions

• No current director, officer, or Affiliate of the Company has outstanding indebtedness to the Company.
• No current director, officer, or Affiliate of the Company is a party to, or directly or indirectly benefits from, any contract, arrangement, or understanding with the Company (other than a Plan) of a type that would be required to be disclosed under Item 404 of Regulation S-K.
• No event has occurred since the Company's last proxy statement to its stockholders that would be required to be reported by the Company in accordance with Item 404 of Regulation S-K.

Stakeholder Impact

• Shareholders will receive a significant cash premium and potential future contingent payments via CVRs, offering immediate value and long-term upside tied to larsucosterol's commercial success.
• Key service providers, including senior management, are eligible for cash retention bonuses tied to the same larsucosterol net sales milestones, incentivizing their continued dedication and aligning their interests with the product's success. Employment terms for continuing employees are protected for at least 12 months post-merger.
• Customers/Patients may benefit from accelerated development and potential commercialization of larsucosterol, a drug with FDA Breakthrough Therapy Designation for alcoholic hepatitis, addressing a high unmet medical need.

Next Steps

• Merger Sub to commence a tender offer for DURECT shares by August 11, 2025.
• DURECT to file a Solicitation/Recommendation Statement on Schedule 14D-9.
• Merger Sub to file a Tender Offer Statement on Schedule TO.
• Consummation of the tender offer, subject to conditions including a majority of outstanding shares tendered.
• Merger of Merger Sub into DURECT to follow the tender offer, with DURECT surviving as a wholly-owned subsidiary of Bausch Health.
• Planning for a registrational Phase 3 program for larsucosterol in severe alcoholic hepatitis.
• Expected efficacy and safety results for Bausch Health's rifaximin SSD Phase 3 program in early 2026.
• DURECT shares to be delisted from Nasdaq and registration terminated under the Exchange Act after the Effective Time.

Key Dates

Recommendation

The acquisition offers DURECT shareholders a substantial immediate cash premium of 217% over the prior day's closing price, significantly de-risking their investment. Additionally, the contingent value rights provide a compelling upside potential of up to $350 million tied to the commercial success of larsucosterol, a drug with FDA Breakthrough Therapy Designation addressing a high unmet medical need. This combination of immediate, high-premium cash and significant future upside makes it a strong buy for existing shareholders to tender their shares.

Keywords

DURECT Corporation, Bausch Health, Acquisition, Merger, Tender Offer, Larsucosterol, Contingent Value Rights, CVR, Alcoholic Hepatitis, Biopharmaceutical, Pharmaceutical, Hepatology, FDA Breakthrough Therapy Designation, Drug Development, Clinical Trials, DRRX, BHC